[PDF][PDF] Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without …

S Tejpar, I Celik, M Schlichting, U Sartorius… - J Clin …, 2012 - researchgate.net
S Tejpar, I Celik, M Schlichting, U Sartorius, C Bokemeyer, E Van Cutsem
J Clin Oncol, 2012researchgate.net
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic
Colorectal Cancer Treated With First-Line Chem Page 1 Association of KRAS G13D Tumor
Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line
Chemotherapy With or Without Cetuximab Sabine Tejpar, Ilhan Celik, Michael Schlichting, Ute
Sartorius, Carsten Bokemeyer, and Eric Van Cutsem Sabine Tejpar and Eric Van Cutsem,
University Hospital Gasthuisberg, Leuven, Belgium; Ilhan Celik, Michael Schlichting, and Ute …
Purpose
We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D–mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
researchgate.net